Medtronic (MDT) Valuation Check As Stealth AXiS And Affera Platforms Reach New Regulatory And Clinical Milestones

Medtronic (MDT) is in focus after two medical technology updates: a CE mark for its Stealth AXiS surgical system in spine and cranial procedures, and fresh clinical milestones for its Affera cardiac arrhythmia platform.

See our latest analysis for Medtronic.

Despite a series of product milestones in cardiac care and surgical robotics, Medtronic’s 1 day share price return of 2.02% to US$80.97 comes against a weaker backdrop. The 90 day share price return shows a 21.36% decline and the 1 year total shareholder return shows a 0.02% decline, suggesting momentum has been fading recently.

If you want to see how other health focused names are positioned around AI driven care and automation, it is worth checking out 33 healthcare AI stocks

With Medtronic delivering new device milestones yet posting a 21.36% 90 day share price decline and a flat 1 year total return, is the current valuation a potential opening for patient investors, or is the market already pricing in future growth?

Most Popular Narrative: 14.8% Undervalued

According to the most followed narrative on Medtronic, the fair value sits at $95 against the last close of $80.97, pointing to a sizeable valuation gap with a moderate discount rate of 8.25% applied to future cash flows.

Diverse Product Portfolio: Medtronic operates across four key segments, Cardiovascular, Medical-Surgical, Neuroscience, and Diabetes, providing revenue stability and reducing dependency on any single product line. This diversification surpasses more specialized competitors like Boston Scientific (focused on cardiovascular) or Intuitive Surgical (robotics).

Read the complete narrative.

Want to see what kind of revenue mix, earnings trajectory, and profitability profile support that higher $95 fair value, and how those inputs shape the narrative’s long term view?

Result: Fair Value of $95 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this narrative still faces pressure from regulatory setbacks or product recalls, and from underperformance in the Diabetes segment, either of which could challenge assumptions behind that US$95 fair value.

Find out about the key risks to this Medtronic narrative.

Next Steps

With sentiment split between recent share price weakness and a higher fair value narrative, it helps to see the inputs yourself rather than rely on headlines. To understand why some investors still see upside potential, take a closer look at the 6 key rewards

Looking for more investment ideas?

If Medtronic has piqued your interest, do not stop here. Broader ideas can help you spot opportunities earlier and avoid overconcentration in a single stock.

• Target resilient income by scanning for reliable payers and potential yield opportunities through the 12 dividend fortresses.
• Hunt for quality at a discount by reviewing companies flagged as potential value opportunities in the 51 high quality undervalued stocks.
• Strengthen your core holdings by checking companies with robust finances in the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com